Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS-3: SOF/VEL/VOX vs SOF/VEL in Genotype 3 HCV with Cirrhosis
NCT02639338Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2015
- Primary completion
- Oct 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of voxilaprevir in chronic hepatitis C genotype 3 (HCV) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinue Study Drug Due to an Adverse Event. Started Dec 2015; status: completed.
02
Drugs
voxilaprevir
03
Conditions
chronic hepatitis C genotype 3 (HCV)
Beyond the preview
Go deeper on NCT02639338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639338.